Catalog No.
PHA37101
Species reactivity
Human, Mouse, Rat
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Human XPO1 (Thr917-Asp1071).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
Exportin-1,XPO1,Chromosome region maintenance 1 protein homolog,CRM1,Exp1
Purification
Purified by antigen affinity column.
Accession
O14980
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Unraveling Venetoclax Resistance: Navigating the Future of HMA/Venetoclax-Refractory AML in the Molecular Era., PMID:40361510
Modulation of anti-tumour immunity by XPO1 inhibitors., PMID:40291981
[How I treat lymphomas associated with HIV infection]., PMID:40134193
Novel Targets and Advanced Therapies in Diffuse Large B Cell Lymphomas., PMID:38927948
Small molecule agents for triple negative breast cancer: Current status and future prospects., PMID:38290250
Treatment of multiple myeloma with selinexor: a review., PMID:38186637
Chronic Lymphocytic Leukemia IGHV Somatic Hypermutation Detection by Targeted Capture Next-Generation Sequencing., PMID:38175592
A novel two-step administration of XPO-1 inhibitor may enhance the effect of anti-BCMA CAR-T in relapsed/refractory extramedullary multiple myeloma., PMID:37964302
Impacting T-cell fitness in multiple myeloma: potential roles for selinexor and XPO1 inhibitors., PMID:37954586
Selinexor With Anti-PD-1 Antibody as a Potentially Effective Regimen for Patients With Natural Killer/T-Cell Lymphoma Failing Prior L-Asparaginase and PD-1 Blockade., PMID:37616529
XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression., PMID:37528310
Treatment options for molecular subtypes of endometrial cancer in 2023., PMID:36943683
Optimal timing and drug combination of selinexor in multiple myeloma: a systematic review and meta-analysis., PMID:36920065
Recent advances in the treatment of multiple myeloma: a brief review., PMID:36225211
The molecular mechanism and challenge of targeting XPO1 in treatment of relapsed and refractory myeloma., PMID:35660848
How I treat triple-class refractory multiple myeloma., PMID:35373352
Guidance for Use and dosing of Selinexor in Multiple Myeloma in 2021: Consensus From International Myeloma Foundation Expert Roundtable., PMID:35361554
Selinexor Enhances NK Cell Activation Against Malignant B Cells via Downregulation of HLA-E., PMID:34926302
Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond., PMID:34680303
A Curious Novel Combination of Nucleophosmin (NPM1) Gene Mutations Leading to Aberrant Cytoplasmic Dislocation of NPM1 in Acute Myeloid Leukemia (AML)., PMID:34573408
Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor., PMID:34434061
Plasticity of Mature B Cells Between Follicular and Classic Hodgkin Lymphomas: A Series of 22 Cases Expanding the Spectrum of Transdifferentiation., PMID:34265801
Targeted Therapies for Multiple Myeloma., PMID:33922567
Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I Study., PMID:33785483
Sequencing multiple myeloma therapies with and after antibody therapies., PMID:33275724
Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma., PMID:33202794
Emerging agents and regimens for multiple myeloma., PMID:33168044
Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody., PMID:33023194
Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study., PMID:32986498
Current developments in the combination therapy of relapsed/refractory multiple myeloma., PMID:32969752
Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection., PMID:32669858
Selinexor: a first-in-class SINE compound for treatment of relapsed refractory multiple myeloma., PMID:32511022
Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma., PMID:32394425
Diagnostic utility of STAT6YE361 expression in classical Hodgkin lymphoma and related entities., PMID:31822802
Novel targets for the treatment of relapsing multiple myeloma., PMID:31125526
Xpo7 is a broad-spectrum exportin and a nuclear import receptor., PMID:29748336
Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma., PMID:29610030
Immunoprecipitation of Tri-methylated Capped RNA., PMID:29527542
Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma., PMID:29381435
Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors., PMID:27557643
Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy., PMID:27226433
Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study., PMID:26819451
Chronic lymphocytic leukemia (CLL)-Then and now., PMID:26690614
A Low Frequency of Losses in 11q Chromosome Is Associated with Better Outcome and Lower Rate of Genomic Mutations in Patients with Chronic Lymphocytic Leukemia., PMID:26630574
XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A., PMID:25878333
NOTCH1 mutations in CLL associated with trisomy 12., PMID:22086416
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia., PMID:21642962
H2O2 sensing through oxidation of the Yap1 transcription factor., PMID:11013218
For research use only. Not for human or drug use.
